Browsing Tag
TRANSCEND
2 posts
Retatrutide development: Phase 3 results, 2027 FDA filing, TRIUMPH trials and what comes next
Eli Lilly and Company’s retatrutide programme has completed the core Phase 3 clinical package supporting planned submissions for obesity, knee osteoarthritis pain and obstructive sleep apnea. The investigational triple hormone receptor agonist is moving toward a U.S. filing in the first quarter of 2027 while additional studies test diabetes, cardiovascular and kidney outcomes, liver disease, chronic pain, maintenance treatment and its performance against tirzepatide.
Rhythm Pharmaceuticals (RYTM) TRANSCEND trial in NEJM shows 19.8% placebo-adjusted BMI reduction
Rhythm Pharma (RYTM) TRANSCEND Phase 3 published in NEJM validates IMCIVREE for acquired hypothalamic obesity. 10,000-patient US market launch trajectory ahead.